Rossari Biotech’s (Rossari) Q2FY27 EBITDA grew 20.9% YoY. While EBITDA margin also improved to 12.5%, it was constrained by elevated freight costs, volatility in raw material prices, and limited availability of Ethylene Oxide (EO).